أصدرت شركة Tenaya Therapeutics, Inc. عرضاً تقديمياً في 17 مايو 2026، يغطي نتائج المرحلة الأولى/الثانية من دراسة RIDGE-1 للعلاج الجيني TN-401. ويركز العرض التقديمي على علاج اعتلال عضلة القلب البطيني الأيمن المحدث لاضطراب النظم المرتبط بـ PKP2.
أصدرت الشركة العرض التقديمي بالتزامن مع مراجعة البيانات السريرية، حيث يوفر تفاصيل حول الدراسة الجارية للمرشح للعلاج الجيني المتداول تحت الرمز TNYA في بورصة ناسداك (NASDAQ). لم يتم تحديد أي نتائج إضافية أو أعداد للمشاركين في مواد البيان الصادر.
من إعداد الذكاء الاصطناعي صورة مولدة بواسطة الذكاء الاصطناعي
A health ministry expert panel has conditionally approved two regenerative medicine products derived from induced pluripotent stem (iPS) cells for treating Parkinson's disease and severe heart disease. This marks a potential world first in commercializing Nobel Prize-winning stem cell technology. The approval, based on small-scale clinical trials confirming safety and presumed efficacy, requires post-market verification within seven years.
Inovio Pharmaceuticals held its first-quarter 2026 earnings call on May 13 to discuss financial results for the period ended March 31 and provide updates on its DNA medicines platform.
من إعداد الذكاء الاصطناعي
ProQR Therapeutics N.V. published its slide deck for a presentation at the TIDES USA 2026 conference. The materials were released on May 15, 2026, in connection with the company's Q1 earnings summary from May 12.
ARS Pharmaceuticals held its first quarter 2026 earnings conference call on May 15, highlighting early momentum in the new year. Company executives emphasized growth drivers including expanded access for its neffy product. The call featured forward-looking statements about the firm's commercial progress.
من إعداد الذكاء الاصطناعي
Sequencio, a new Hong Kong unit of CK Life Sciences, is advancing about 20 cancer vaccine projects via China's faster pathway to human trials. CK Life Sciences vice-president and chief scientific officer Dr Melvin Toh Kean-meng said the firm plans investigator-initiated trials next year.
A single injection of gene therapy has significantly improved hearing in all ten patients born with a genetic form of deafness, according to a new study. Researchers delivered a working copy of the OTOF gene into the inner ear, with most patients regaining hearing within one month. The treatment, tested in China, proved safe and effective across ages from one to 24.
من إعداد الذكاء الاصطناعي تم التحقق من الحقائق
Doctors at Keck Medicine of USC are implanting lab-grown, dopamine-producing cells into the brains of people with Parkinson’s disease in an early-stage clinical trial that will enroll up to 12 participants across three U.S. sites.